BioSpace News Archive

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2021 second quarter financial results on Tuesday, August 3, 2021 after the close of the financial markets.

AnPac Bio-Medical Science Co., Ltd., a biotechnology company with operations in China and the United States focused on early cancer screening and detection as well as cancer treatment, pre-announced that it has experienced strong growth in test volume in the first half year of 2021, with total number of paid customers and testing volume increasing almost 110% compared with the same period in 2020.

Sol-Gel Technologies, Ltd., a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, will report second quarter 2021 financial results on Wednesday, August 4, 2021 at 7:05 AM ET.

MediWound Ltd., a fully-integrated biopharmaceutical company focused on next-generation bio-therapeutics solutions for tissue repair and regeneration, announced positive topline results from its pivotal phase 3 pediatric clinical study with NexoBrid® to treat children with severe thermal burns, evaluating the efficacy and safety compared with standard-of-care.

ADMA Biologics, Inc., an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, announced the United States Food and Drug Administration recently completed a Pre-Approval Inspection of the Boca Raton, FL manufacturing facility related to ADMA’s application for its VanRx SA25 Workcell aseptic fill-finish machine.

Mevion Medical Systems announced today that it has delivered the 15-ton compact accelerator to Mercy Hospital St. Louis in Missouri.

EQRx today announced the formation of its mission advisory board.

Beyond Air, Inc. today announced that it will report financial results for its first fiscal quarter ended June 30, 2021 on Tuesday, August 10, 2021.

Oncology Pharma Inc. (OTC PINK:ONPH) Oncology Pharma, Inc. is laying out and taking necessary steps to move its licensed IP forward.

Creative Medical Technology Holdings Inc. announced today the launching of its second Regenerative Immunology product, MyeloCelz™.